Beaufort Securities reiterated Venn Life Sciences Holdings PLC (LON:VENN) to Speculative Buy in a report released today.
- Updated: September 18, 2016
Just yesterday Venn Life Sciences Holdings PLC (LON:VENN) traded 0.00% even at 30.00GBX. Venn Life Sciences Holdings PLC’s 50-day average is 28.43GBX and its 200-day average is 25.63GBX. With the last stock price close up 11.12% from the two hundred day moving average, compared to the S&P 500 Index which has fallen -0.01% over the same time. Trading volume was was down over the average, with 27,000 shares of VENN changing hands under the typical 60,542 shares..
Beaufort Securities has reiterated Venn Life Sciences Holdings PLC(LON:VENN) to Speculative Buy in a statement released 8/04/2016.
Recent Performance Graph:
With a market cap of 0.0 GBX, Venn Life Sciences Holdings PLC has a one-year low of 17.55GBX and a one-year high of 30.30GBX with a price-earnings ratio of 0.
Brief Synopsis About Venn Life Sciences Holdings PLC (LON:VENN)
Venn Life Sciences Holdings plc is a clinical research organization (CRO), which is engaged in providing a suite of consulting and clinical trial services to pharmaceutical, biotechnology and medical device organizations. The Company has the innovation segment, which is focused on developing and commercializing skin technologies. It provides drug development services through its subsidiary, Kinesis Pharma B.V. The Company’s drug development services include clinical development, pharmaceutical development, non-clinical/pre-clinical development, drug candidate selection and drug development project management. The Company offers international clinical research services, including protocol development; feasibility and site selection; investigator and site selection; project management; site management and monitoring; vendor management, and quality assurance. The Company has its presence in the United Kingdom, Ireland, France, Netherlands, and Germany and Singapore.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.